ZL-2102

ZL-2102 is an orally administered small molecule inhibitor of hematopoietic prostaglandin D synthase (H-PGDS). It was originally developed by Sanofi and later licensed to Zai Lab for further development. The drug is being investigated primarily for chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis. Its mechanism of action involves inhibition of H-PGDS, which plays a role in the biosynthesis of prostaglandin D2—a mediator implicated in inflammation and allergic responses. Clinical trials have focused on evaluating its safety, tolerability, pharmacokinetics, and food effect in healthy volunteers[1][2][3][4][5].